Pharmacologic Treatment of Attention-Deficit/Hyperactivity Disorder: Efficacy, Safety and Mechanisms of Action
The DOI matches its Crossref record; 100 of the 100 references it cites were found in a registry or an index.
Abstract
Studies examining the efficacy, safety and mechanisms of action of agents for the treatment of attention-deficit/hyperactivity disorder (ADHD) are reviewed, with an emphasis on newer agents such as the long acting stimulants and atomoxetine. Recent studies of medications are characterized by large, rigorously diagnosed samples of children, adolescents and adults with ADHD, use of standardized rating scales and extensive safety data. These studies confirm a robust treatment effect for the Food and Drug Administration approved agents ranging from 0.7 to 1.5. The most common short term side effects to the most commonly used agents include insomnia, loss of appetite, and headaches. Despite public controversy and labeling changes to warn of extremely rare cardiovascular and psychiatric side effects, the evidence does not support the hypothesis that medication for ADHD increases risk for sudden death, mania or psychosis. A wide variety of neuroimaging techniques including electrocephalogram (EEG) power, event related potentials (ERP), functional magnetic resonance imaging (fMRI), and positron emission tomography (PET) are beginning to examine the mechanisms of action of medications for ADHD, and implicating the catecholamines and prefrontal and anterior cingulate cortices as prime sites of actions for these agents.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“evidence from a large body of studies showed that treatment responses from different patients are widely different in terms of the types of pharmacological treatments, dosage requirements, tolerability, response rates, and adverse-event profiles (Spencer et al., 1996; Efron et al., 1997; Pliszka, 2007; Newcorn et al., 2008; Victor et al., 2009; Wilens et al., 2011; Hodgkins et al., 2012).”
From A Review of Heterogeneity in Attention Deficit/Hyperactivity Disorder (ADHD) (2019) · cites this paper as Pliszka, 2007
In the citing paper
“pharmacological treatment has limitations including unfavorable side effects for some patients [8]”
From Proof-of-concept study of an at-home, engaging, digital intervention for pediatric ADHD (2018) · cites this paper as [8]
Citations
Cites
ADHD and The Nature of Self-Control
Barkley, R. A., & Wasserstein, J. (2000) · Journal of Cognitive Psychotherapy · doi:10.1891/0889-8391.14.1.111 · Cited by 1,513
ADHD and the Nature of Self-Control
Hinshaw, S. P. (1998) · Journal of Developmental & Behavioral Pediatrics · doi:10.1097/00004703-199806000-00010 · Cited by 1,194
Suicidality in Pediatric Patients Treated With Antidepressant Drugs
Hammad, T. A., Laughren, T., & Racoosin, J. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.3.332 · Cited by 1,054
THE BEHAVIOR OF CHILDREN RECEIVING BENZEDRINE
Bradley, C. (1937) · American Journal of Psychiatry · doi:10.1176/ajp.94.3.577 · Cited by 1,035
Volkow, N. D., Wang, G.-J., Fowler, J. S., Gatley, S. J., Logan, J., Ding, Y.-S., Hitzemann, R., & Pappas, N. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.10.1325 · Cited by 885 · cited 2×
“transporters in the striatum (Volkow et al., 1998).”
BackgroundInfluentialBush, G., Frazier, J. A., Rauch, S. L., Seidman, L. J., Whalen, P. J., Jenike, M. A., Rosen, B. R., & Biederman, J. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00083-9 · Cited by 866 · cited 2×
“…comparisons of ADHD children to controls during fMRI have shown differences in fronto-striatal activity (Bush, Valera, & Seidman, 2005), particularly in the right prefrontal cortex (Rubia, Smith, Brammer, Toone, & Taylor, 2005) and anterior cingulate (Bush et al., 1999; Pliszka et al., 2006b).”
BackgroundVaidya, C. J., Austin, G., Kirkorian, G., Ridlehuber, H. W., Desmond, J. E., Glover, G. H., & Gabrieli, J. D. E. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.24.14494 · Cited by 845 · cited 1×
“Initially, Vaidya et al. (1998) showed that MPH, relative to placebo, increased frontal activation in both children with ADHD and controls.”
BackgroundPharmacotherapy of Attention-Deficit Hyperactivity Disorder across the Life Cycle
SPENCER, T., BIEDERMAN, J., WILENS, T., HARDING, M., O'DONNELL, D., & GRIFFIN, S. (1996) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199604000-00008 · Cited by 830 · cited 2×
“were found in 161 studies encompassing 5 preschool, 140 school age, 7 adolescent and 9 adult RCTs (Spencer et al., 1996).”
BackgroundBarry, R. J., Clarke, A. R., & Johnstone, S. J. (2003) · Clinical Neurophysiology · doi:10.1016/s1388-2457(02)00362-0 · Cited by 819 · cited 1×
“Healthy controls produce a larger P300 wave to the oddball tones than to the common tones, but this difference is markedly reduced in children with ADHD (Barry et al., 2003).”
BackgroundAtomoxetine in adults with ADHD: two randomized, placebo-controlled studies
Michelson, D., Adler, L., Spencer, T., Reimherr, F. W., West, S. A., Allen, A. J., Kelsey, D., Wernicke, J., Dietrich, A., & Milton, D. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01671-2 · Cited by 790 · cited 7×
“Thus it is tempting to conclude that MPH increases the allocation of mental resources to a task, but Springer further studies have not borne this out.”
BackgroundInfluential
Cited by
Items 101–156 of 156
Ondrejka, I., Abalı, O., Paclt, I., Gácser, M., Iftene, F., Walton, R., Harrison, G., Treuer, T., & Martényi, F. (2010) · International Journal of Psychiatry in Clinical Practice · doi:10.3109/13651500903556511 · Cited by 5
Leffa, D. T., Panzenhagen, A. C., Rovaris, D. L., Bau, C. H. D., Rohde, L. A., Grevet, E. H., & Pires, G. N. (2018) · BMJ Open Science · doi:10.1136/bmjos-2018-000001 · Cited by 4
“Although promoting overall clinical improvement, there is a substantial heterogeneity regarding the response to MPH treatment,(18) and about 30% of patients do not present a clinical response.(19) Therefore, a well-validated animal model is also essential in order to have a proper tool to understand the variability in…”
BackgroundAttention Deficit Hyperactivity Disorder
Jones, H. A., Rabinovitch, A. E., Eddy, L. D., & Wilson, S. A. (2016) · Springer eBooks · doi:10.1007/978-3-319-25501-9_18 · Cited by 5
Behandeling van jeugdigen met een psychiatrische stoornis en een verstandelijke beperking
de Koning, N., & Collin, P. J. L. (2007) · Kind en adolescent · doi:10.1007/bf03061032 · Cited by 6
Clemow, D. B., Mason, O., Sarkis, E. H., Ruff, D. D., Berman, B. D., Donnelly, C. L., Robb, A. S., Holland, D., Schuh, K. J., Barnes, J. M., et al. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1102060 · Cited by 5
“[3,4] Pharmacological treatments for ADHD have been shown to be very effective therapies, [5,6] and include short-acting, intermediateacting and long-acting formulations of methylphenidate, dexmethylphenidate, amphetamine (including mixed salt formulations), dextroamphetamine and prodrug lisdexamfetamine dimesylate st…”
BackgroundTowards a Biological Understanding of ADHD and the Discovery of Novel Therapeutic Approaches
Tannock, R., Campbell, B., Seymour, P. A., Ouellet, D., Soares, H. D., Wang, P., & Chappell, P. B. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-373861-5.00010-2 · Cited by 4
Wang, Y., Liu, Q., Liu, M., Wang, W., Ye, S., Liu, X., Liang, H., Xue, X., & Gao, H. (2024) · Journal of Neurophysiology · doi:10.1152/jn.00290.2024 · Cited by 3
Disruptive Mood Dysregulation, and Other Disruptive or Aggressive Disorders in ADHD
Blader, J. C. (2017) · Springer eBooks · doi:10.1007/978-3-319-64251-2_6 · Cited by 5
Uebel, H., Dangel, O., Fischer, R., Ruhmann, M., & Huß, M. (2021) · Scandinavian Journal of Child and Adolescent Psychiatry and Psychology · doi:10.21307/sjcapp-2021-009 · Cited by 4
Golden, C. (2009) · OhioLink ETD Center (Ohio Library and Information Network) · Cited by 3
Long-term Efficacy of ADHD Pharmacotherapy in Children
Gilchrist, R. H., & Arnold, L. E. (2008) · Psychiatric Annals · doi:10.3928/00485713-20080101-03 · Cited by 3
Matsuo, T., Oshima, S., Kunii, Y., Okano, T., Yabe, H., & Niwa, S. (2014) · Open Journal of Psychiatry · doi:10.4236/ojpsych.2014.44046 · Cited by 2
“Methylphenidate, which has been used as a therapeutic drug, selectively targets dopamine and noradrenaline transporters and supposedly activates dopamine and noradrenaline receptors in order to increase attention levels [11].”
BackgroundBloch, M. H., Gorman, D. A., & Abi‐Jaoude, E. (2012) · Evidence-Based Child Health A Cochrane Review Journal · doi:10.1002/ebch.1862 · Cited by 3
Effects of methylphenidate on impulsive choice and delay aversion in Lewis rats
Panfil, K., Small, R., & Kirkpatrick, K. (2023) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000719 · Cited by 2
“Lewis rats should make more impulsive choices than Wistars (their outbred source strain), and methylphenidate should increase self-controlled choices in Lewis rats, similar to the effects produced when methylphenidate is administered to children and adults with ADHD (Pliszka, 2007; Kolar et al., 2008).”
BackgroundMethylphenidate Conditioned Place Preference in Juvenile and Adolescent Male and Female Rats
Freeman, E. D. (2013) · Digital Commons - East Tennessee State University (East Tennessee State University) · Cited by 4
Daviss, W. B. (2017) · Springer eBooks · doi:10.1007/978-3-319-64251-2_7 · Cited by 5
Mindfulness-Based Attention as a Moderator of the Relationship Between ADHD and Comordid Disorders
Jacobs, A. (2011) · CommonKnowledge Research Repository (Pacific University Oregon) · Cited by 2
Tempo cognitivo lento: una revisión actualizada
Ustárroz, J. T., Ruiz-García, B., Luna-Lario, P., & Goñi, P. H. (2015) · Revista de Neurología · doi:10.33588/rn.6107.2015327 · Cited by 13
“Por otro lado, los pacientes con los otros dos subtipos de TDAH (hiperactivo y combinado) de manera característica aparentan tener una energía excesiva y no tienen dificultades en el procesamiento de información [29, 38,39].”
BackgroundTherapeutic Use of Dopamine Enhancers (Stimulants)
Zuddas, A., & Carucci, S. (2023) · Springer eBooks · doi:10.1007/978-3-030-42825-9_138-1 · Cited by 1
Namipashaki, A., Yu, H., Bellgrove, M. A., & Hawi, Z. (2026) · Cells · doi:10.3390/cells15100931 · Cited by 2
“Pharmacological evidence including stimulant medications (methylphenidate and amphetamine), block dopamine and norepinephrine transporters and increase synaptic catecholamine levels, are the first-line treatment for ADHD and demonstrate strong clinical efficacy [11].”
Price, J. W. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4359 · Cited by 2
Sustainable change: Treatment adherence in ADHD
Manos, M. J. (2014) · Cambridge University Press eBooks · doi:10.1017/cbo9781139035491.029 · Cited by 1
Chapter 9. Neurodevelopmental Disorders
Hong, D. S., Fung, L. K., & Hardan, A. Y. (2019) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615372980.lr09 · Cited by 1
Neurocognitive deficits in adult ADHD : preclinical and clinical studies
Tomlinson, A. (2014) · Research Explorer (The University of Manchester) · Cited by 1
Ziereis, S. (2015) · University of Regensburg Publication Server (University of Regensburg) · doi:10.5283/epub.31326 · Cited by 1
Wagner, S. (2011) · The Research Repository @ WVU (West Virginia University) · doi:10.33915/etd.4811 · Cited by 3
“Stimulant medications have been researched in hundreds of studies and these medications are considered one of the best studied psychiatric pharmacological treatments (Pliszka, 2007).”
BackgroundAranas, K. (2020) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r3-sszt-t778 · Cited by 1
Attention‐ D eficit/Hyperactivity Disorder
Acosta, M. T., Arcos‐Burgos, M., & Muenke, M. (2009) · Wiley eBooks · doi:10.1002/9780470478509.neubb002053 · Cited by 1
Attention-Deficit Hyperactivity Disorder
Sinha, J. K., Durgvanshi, S., & Ghosh, S. (2019) · Springer eBooks · doi:10.1007/978-3-319-47829-6_1057-1 · Cited by 1
Carmichael, J. A. (2014) · Libraries and Cultural Resources (University of Calgary) · doi:10.5072/prism/26897
ADHD: EN NEUROBIOLOGISK FORSTYRRELSE?
Habekost, T. (2010) · Psyke & Logos · doi:10.7146/pl.v31i2.8479 · Cited by 1
Factors Influencing Teacher Acceptability of Evidence-Based Interventions for the Treatment of ADHD
Lal, M. G. (2014) · The Scholarship East Carolina University's Institutional Repository (East Carolina University)
Bandel, T. (2013) · Psihološka obzorja · doi:10.20419/2012.21.369 · Cited by 5
Aufmerksamkeitsdefizit-Hyperaktivitätsstörung im Erwachsenenalter
Hölter, T. (2016) · Springer eBooks · doi:10.1007/978-3-662-50315-7_1
Pourmohamadreza‐Tajrishi, M., Ashori, M., Jalil-Abkenar, S. S., & Beh‐Pajooh, A. (2014)
Weaver, C., & Vigliotti, R. (2017) · CommonKnowledge Research Repository (Pacific University Oregon)
Bertaglia, E. B. (2017) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.10.2017.tde-22062017-121424
Bull, S. C. (2006) · Trinity Student Medical Journal
Mind Wandering as a Mechanism of Attentional Dysfunction among Children with ADHD
Merrill, B. M. (2020) · FIU - Digital Commons (Florida International University) · doi:10.25148/etd.fidc008991
“We also hypothesize that stimulant medication would lead to improved seatwork productivity based on decades of research documenting the salutary effects of stimulants on productivity (Carlson et al., 1992; Pelham et al., 1993; Pelham et al., 1995; Pelham et al., 2001; Pliszka, 2007).”
BackgroundResultAssessment of the lamina cribrosa in attention-deficit hyperactivity disorder
Akkaya, S., Ulusoy, D. M., Doğan, H., & Arslan, M. E. (2021) · Indian Journal of Ophthalmology · doi:10.4103/ijo.ijo_562_21
“dopamine and norepinephrine) within the prefrontal cortex have been hypothesized to cause ADHD; and administration of methylphenidate (MPH) and amphetamines have been used to help correct this imbalance.[5,6] MPH inhibits the reuptake of dopamine and noradrenaline in the synaptic cleft.”
Background(2010) · Wiley eBooks · doi:10.1002/9781118269954.refs
Bartolo, C. A. D., & Braun, M. K. (2017) · Springer eBooks · doi:10.1007/978-3-319-49547-7_10
Hong, D. S., Fung, L. K., & Hardan, A. Y. (2019) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615371501.lr09
Pavelka, L. C. (2011) · Springer eBooks · doi:10.1007/978-0-387-79061-9_651
Kızıltoprak, H., Kocabaş, D. Ö., Aydemir, G. A., Kalınlı, E. M., Aydemır, E., & Ören, B. (2022) · Journal of Pediatric Ophthalmology & Strabismus · doi:10.3928/01913913-20221026-01
Uso de cannabis no Transtorno de Déficit de Atenção/Hiperatividade (TDAH): uma revisão de escopo
Mendes, M. C., de Aveiro, B. D. A. H., & Herzog, M. V. M. (2024) · Journal Archives of Health · doi:10.46919/archv5n3espec-587
Therapeutic Use of Dopamine Enhancers (Stimulants)
Zuddas, A., & Carucci, S. (2024) · Springer eBooks · doi:10.1007/978-3-030-51366-5_138
(2019) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615372980.lrindex
(2019) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615372980.lrbm01
Long-term Efficacy of ADHD: Pharmacotherapy in Children
Gilchrist, R. H., & Arnold, L. E. (2008) · Pediatric Annals · doi:10.3928/0090-4481-20080101-10 · Cited by 1
Qunxi, L. U. (2026) · The Asian Educational Therapist · doi:10.64663/aet.66
Wang, A., Li, L., Zhang, T., Yan, P., & Song, Y. (2026) · doi:10.2196/preprints.103352
Lopez-Williams, A. (2010) · Springer eBooks · doi:10.1007/978-1-4419-7780-9_16
“According to common practice parameters espoused by groups such as the American Academy of Pediatrics and The American Academy of Child and Adolescent Psychiatry (Pliszka, 2007; Pliszka et al. 2003), pharmacological treatment of child and adolescent mental health disorders should be conducted in a fashion that include…”
Method
Metadata
- Authors
- Pliszka, S. R.
- Affiliations
- The University of Texas at San Antonio Health Science Center (US)
- Corresponding author
- Pliszka, Steven R.
- ORCID
- Pliszka, Steven R.
- Venue
- Neuropsychology Review
- Published
- 2007-01-23
- Volume
- 17
- Issue
- 1
- Pages
- 61-72
- ISSN
- 1040-7308 (ISSN-L)
- 1573-6660
- OpenAlex
- W2081088104
- Cited by
- 158
- References
- 99
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 3 · 2023: 4 · 2022: 9 · 2021: 3 · 2020: 10 · 2019: 11 · 2018: 2 · 2017: 13 · 2016: 10 · 2015: 7 · 2014: 12 · 2013: 5 · 2012: 12
- FWCI
- 1.92
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychology Review (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Social Sciences › Psychology › Neuropsychology and Physiological Psychology › Developmental and Educational Neuropsychology
- Keywords
- attention deficit hyperactivity disorder, pharmacotherapy, long-acting stimulants, atomoxetine, drug efficacy, drug safety, adverse effects, sudden death risk, mechanism of action, catecholamines, prefrontal cortex, anterior cingulate cortex, neuroimaging
- MeSH terms
- Atomoxetine Hydrochloride, Central Nervous System Stimulants, Attention Deficit Disorder with Hyperactivity, Decision Trees, Humans, Propylamines, Neurotransmitter Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.